|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,807.70 INR | +0.75% |
|
+1.43% | +5.12% |
| 06-10 | Organon wins US approval to widen use of arthritis biosimilar drug | RE |
| 06-09 | Organon Acquisition May Receive $1 Billion Commitment From State Bank of India | MT |
| Market Cap | 4,337B 45.61B 39.41B 36.32B 34.02B 63.81B 64.76B 430B 167B 2,110B 171B 168B 7,309B | P/E Ratio 2026 |
36.8x | P/E Ratio 2027 * | 33x |
|---|---|---|---|---|---|
| Enterprise Value | 4,113B 43.25B 37.38B 34.44B 32.26B 60.51B 61.41B 408B 159B 2,001B 162B 159B 6,931B | EV / Sales 2026 |
6.72x | EV / Sales 2027 * | 6.23x |
| Free-Float |
44.39% | Yield 2026 |
0.91% | Yield 2027 * | 0.86% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.75% | ||
| 1 week | +1.43% | ||
| Current month | +0.47% | ||
| 1 month | -2.06% | ||
| 3 months | -0.96% | ||
| 6 months | +0.79% | ||
| Current year | +5.12% |
| 1 week | 1,766.1 |  | 1,814.5 |
| 1 month | 1,756.8 | | 1,916.6 |
| Current year | 1,583.7 | | 1,916.6 |
| 1 year | 1,548 | | 1,916.6 |
| 3 years | 977.3 | | 1,960.35 |
| 5 years | 652.7 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 25/05/2018 | |
| Director/Board Member | 70 | 21/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.75% | +1.43% | +7.13% | +83.44% | 45.63B | |
| -0.20% | -3.59% | +38.01% | +87.26% | 33.53B | |
| +0.44% | -0.85% | -7.55% | +44.74% | 11.81B | |
| -0.11% | +1.44% | +12.86% | +116.61% | 11.69B | |
| +0.59% | +0.78% | +36.70% | +126.43% | 9.12B | |
| +2.40% | +0.08% | +17.77% | +43.22% | 7.16B | |
| -1.12% | -0.56% | +40.12% | -18.60% | 6.49B | |
| +1.37% | +0.35% | +32.58% | +240.43% | 6.45B | |
| +0.51% | -3.04% | -42.24% | -5.52% | 5.16B | |
| -0.39% | +5.19% | +14.68% | +117.63% | 4.11B | |
| Average | +0.42% | +0.45% | +15.01% | +83.56% | 14.12B | |
| Weighted average by Cap. | +0.40% | -0.14% | +17.26% | +84.83% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 583B 6.13B 5.29B 4.88B 4.57B 8.57B 8.7B 57.81B 22.49B 283B 22.99B 22.5B 982B | 654B 6.88B 5.94B 5.48B 5.13B 9.62B 9.76B 64.89B 25.25B 318B 25.81B 25.26B 1,102B |
| Net income | 116B 1.22B 1.05B 971M 909M 1.71B 1.73B 11.5B 4.48B 56.38B 4.57B 4.48B 195B | 133B 1.39B 1.21B 1.11B 1.04B 1.95B 1.98B 13.16B 5.12B 64.52B 5.23B 5.12B 224B |
| Net Debt | -224B -2.36B -2.04B -1.88B -1.76B -3.3B -3.35B -22.25B -8.66B -109B -8.85B -8.66B -378B | -264B -2.77B -2.4B -2.21B -2.07B -3.88B -3.94B -26.18B -10.18B -128B -10.41B -10.19B -445B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/26 | 1,807.70 ₹ | +0.75% | 1,243,362 |
| 11/06/26 | 1,794.20 ₹ | +0.44% | 1,858,093 |
| 10/06/26 | 1,786.40 ₹ | +0.42% | 1,882,009 |
| 09/06/26 | 1,779.00 ₹ | -0.55% | 3,756,570 |
| 08/06/26 | 1,788.80 ₹ | +0.37% | 3,098,542 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition